Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:58 pm Purchase | 2023-12-31 | 13G | AlTi Global, Inc. ALTI | CITADEL ADVISORS LLC | 441 0.000% | 441 (New Position) | Filing History |
| 2024-02-14 4:58 pm Purchase | 2023-12-31 | 13G | Inflection Point Acquisition Corp. II IPXX | CITADEL ADVISORS LLC | 3,666 0.000% | 3,666 (New Position) | Filing History |
| 2024-02-14 4:58 pm Purchase | 2023-12-31 | 13G | Alchemy Investments Acquisition Corp 1 ALCY | CITADEL ADVISORS LLC | 1,985 0.000% | 1,985 (New Position) | Filing History |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | 2seventy bio, Inc. TSVT | CITADEL ADVISORS LLC | 146,401 0.300% | -2,445,205 (-94.35%) | Filing History |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | Arhaus, Inc. ARHS | CITADEL ADVISORS LLC | 450,504 0.900% | -2,437,203 (-84.40%) | Filing History |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | PMV Pharmaceuticals, Inc. PMVP | CITADEL ADVISORS LLC | 1,236,850 2.400% | -1,022,891 (-45.27%) | Filing History |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | Semper Paratus Acquisition Corporation LGST | CITADEL ADVISORS LLC | 5,846 0.000% | -927,608 (-99.37%) | Filing History |
| 2024-02-14 4:58 pm Purchase | 2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN | CITADEL ADVISORS LLC | 2,394,448 5.800% | 95,692 (+4.16%) | Filing History |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | Annexon, Inc. ANNX | CITADEL ADVISORS LLC | 1,069,087 1.400% | -1,431,220 (-57.24%) | Filing History |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX | CITADEL ADVISORS LLC | 390,512 0.700% | -2,292,302 (-85.44%) | Filing History |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | Design Therapeutics, Inc. DSGN | CITADEL ADVISORS LLC | 1,834,854 3.300% | -1,036,413 (-36.10%) | Filing History |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | Western Alliance Bancorporation WAL | CITADEL ADVISORS LLC | 2,705,253 2.500% | -3,230,285 (-54.42%) | Filing History |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | Allakos Inc. ALLK | CITADEL ADVISORS LLC | 3,304,622 3.800% | -1,462,307 (-30.68%) | Filing History |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | Icosavax, Inc. ICVX | CITADEL ADVISORS LLC | 283,079 0.600% | -1,906,390 (-87.07%) | Filing History |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | Coherus BioSciences, Inc. CHRS | CITADEL ADVISORS LLC | 2,047,286 1.800% | -3,767,788 (-64.79%) | Filing History |
| 2024-02-14 4:58 pm Purchase | 2023-12-31 | 13G | Janux Therapeutics, Inc. JANX | CITADEL ADVISORS LLC | 3,125,897 6.800% | 999,762 (+47.02%) | Filing History |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | Nektar Therapeutics NKTR | CITADEL ADVISORS LLC | 5,635,132 3.000% | -4,094,620 (-42.08%) | Filing History |
| 2024-02-14 4:58 pm Purchase | 2023-12-31 | 13G | Dutch Bros Inc. BROS | CITADEL ADVISORS LLC | 4,073,886 6.500% | 865,013 (+26.96%) | Filing History |
| 2024-02-14 4:58 pm Purchase | 2023-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS | CITADEL ADVISORS LLC | 5,406,089 7.600% | 1,819,325 (+50.72%) | Filing History |
| 2024-02-14 4:58 pm Purchase | 2023-12-31 | 13G | Expensify, Inc. EXFY | CITADEL ADVISORS LLC | 2,794,376 4.000% | 82,713 (+3.05%) | Filing History |